$25m market cap
$0.17 last close
BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.
BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially available in late 2019 or early 2020 and eventually operating independently.